PaySign (PAYS) Climbs +62% in 30 Days on Strong Q2 Results
Key Takeaways
- PaySign (PAYS) shares climbed roughly 62% over the 30-day period, rising from an adjusted close of $8.69 to about $14.09.
- The move was driven primarily by better-than-expected second-quarter 2026 results reported on August 5, 2026, including a 48% year-over-year revenue increase and a raised full-year outlook.
- Patient Affordability revenue surged nearly 89% year-over-year, while the plasma segment showed a continued recovery.
- Analysts responded with higher price targets and a consensus "Buy" rating, and the stock reached a new 52-week high.
- The quarterly trend is even stronger, with shares roughly doubling over the trailing three months.
PaySign's Business and Market Position
PaySign, Inc. (NASDAQ: PAYS) is a Henderson, Nevada-based financial technology company that provides prepaid card programs, patient affordability offerings, digital banking, and integrated payment processing services. Founded in 2001, the company serves pharmaceutical manufacturers, plasma collection centers, corporations, and government institutions through its cloud-based Paysign platform.
The business centers on two main verticals. Its Patient Affordability solutions help pharmaceutical companies administer copay assistance and reimbursement programs, while its plasma segment provides prepaid donor compensation cards to plasma collection centers. PaySign has also expanded into life science technology through its Apherion donor management system, which is currently under regulatory review. I find the stock interesting for its exposure to high-growth healthcare payment niches, recurring revenue model, and track record of expanding margins and profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
PAYS Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, PaySign shares advanced approximately 62%, moving from an adjusted closing price of $8.69 to about $14.09. The rally accelerated sharply after the company reported second-quarter results, with the stock jumping 29% in a single session as trading volume expanded well above its daily average.
The quarterly picture stands out even more. Roughly three months earlier, shares traded near $6.72, meaning the stock has roughly doubled—up about 110%—over the trailing quarter. This sustained upward trend reflects improving fundamentals, a plasma inventory overhang that has largely normalized, and accelerating growth in the higher-margin Patient Affordability business. From what I see, these moves highlight how quickly sentiment can shift with solid execution.
Key Drivers Behind the Recent 30-Day Rally
The primary catalyst for the 30-day surge was PaySign's second-quarter 2026 earnings report, released after the market close on August 5, 2026. The company posted total revenue of $28.25 million, up 48.1% year-over-year and above consensus estimates, while earnings per share of $0.11 beat the consensus forecast of $0.06 by $0.05.
Growth was led by the Patient Affordability segment, where revenue increased 88.9% year-over-year to $14.6 million on higher claim volume and the launch of 13 new programs, bringing the total to 148 active programs. Plasma revenue rose 21.4% to $13.0 million, and average monthly revenue per center reached its highest level since the third quarter of 2024. Gross margin expanded 170 basis points to 63.3%, while adjusted EBITDA grew 113% to $9.6 million.
Management also raised its full-year 2026 guidance to revenue of $114 million to $117 million (implying 39% to 43% growth) and adjusted EBITDA of $35 million to $38 million, alongside above-consensus third-quarter guidance. Analysts reacted quickly, with DA Davidson, Lake Street Capital, and Barrington Research raising price targets following the report. The stock subsequently set a new 52-week high as institutional and retail interest increased. One thing that stands out here is how the beat-and-raise combination reinforced confidence in the growth story.
Broader Factors Behind the Quarterly Gains
The quarterly rally reflects a broader re-rating of PaySign as its business model demonstrated operating leverage at scale. Over the trailing three months, the company has consistently shown that Patient Affordability revenue can sustain rapid growth while the plasma segment recovers from the inventory overhang that pressured results through 2025.
Investor sentiment also improved as PaySign signaled international ambitions, establishing an Ireland-based subsidiary to pursue a global plasma software market opportunity. The company's dynamic business rules technology has shielded clients from more than $300 million in costs in the first half of 2026, reinforcing the value proposition behind its platform. Together, these developments shifted the narrative from a recovering plasma provider to a diversified healthcare payments growth story, supporting the stock's sustained upward trend. I'm watching this closely as execution on these fronts could influence longer-term valuation.
What to Watch Next for PAYS
Looking ahead, investors will monitor PaySign's third-quarter 2026 results, with the company guiding for revenue of $28.5 million to $30.0 million and EPS of $0.09 to $0.10. Seasonal patterns typically moderate pharmaceutical claim volume in the second half of the year, so sequential growth trends will be closely watched.
Key items on the horizon include the timing of FDA review for the Apherion donor management system, progress on international expansion through the new Ireland subsidiary, and the pace of new patient affordability program wins. Investors should also weigh concentration risk in the Patient Affordability segment, continued plasma center consolidation, and an expected rise in the effective tax rate later in the year. These factors may influence how the market assesses PaySign's growth trajectory and valuation in the coming quarters.
Exploring AI Tools for Market Analysis
I often turn to Tickeron’s Trending AI Robots to review algorithmic trading bots that monitor thousands of tickers. The page highlights top-performing bots with details on strategy, timeframe, and performance metrics, which helps me explore data-driven approaches alongside my own analysis of names like PaySign.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
PAYS in +2.10% Uptrend, rising for three consecutive days on August 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PAYS advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on PAYS as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PAYS just turned positive on August 05, 2026. Looking at past instances where PAYS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 226 cases where PAYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAYS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PAYS broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PAYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.228) is normal, around the industry mean (22.706). P/E Ratio (54.192) is within average values for comparable stocks, (70.701). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.165). PAYS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.021). P/S Ratio (8.703) is also within normal values, averaging (111.934).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of payment solutions
Industry ComputerCommunications
Advertisement